Pfizer Sees 55% Upside on 7% YoY Sales Growth and Pipeline Catalysts
PFE•Pfizer is rated Buy with over 55% upside potential over two years, reflecting undervalued forward earnings and a robust late-stage pipeline. Its Q1 non-COVID sales rose 7% year-over-year, boosted by Seagen contributions and new product launches, while GLP-1 candidate berobenatide and pending patent settlements underpin growth.
1. Analyst Buy Rating and Upside Target
An analyst projects over 55% upside for Pfizer shares over the next two years, attributing this to undervalued forward earnings multiples and a deep late-stage pipeline poised to drive revenue beyond current forecasts.
2. Q1 2026 Sales and Earnings Performance
In the first quarter of 2026, Pfizer’s non-COVID revenue grew 7% year-over-year, led by strong contributions from its Seagen acquisition and new product launches, marking a beat on consensus estimates.
3. Late-Stage Pipeline Catalysts
The GLP-1 candidate berobenatide is highlighted as a potential blockbuster, while aggressive oncology growth strategies are expected to bolster top-line expansion in coming years.
4. Patent Settlements Extending Revenue Streams
Recent patent settlement agreements are set to extend exclusivity on key medicines, providing a cushion against generic competition and supporting long-term earnings visibility.
